NDAORALCAPSULE
Approved
Jul 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNALGOS-DC is a fixed-dose oral capsule combining aspirin, caffeine, and dihydrocodeine bitartrate, a Schedule II opioid analgesic. It is indicated for moderate pain relief where opioid therapy is appropriate. The combination leverages aspirin's anti-inflammatory action, caffeine's analgesic potentiation, and dihydrocodeine's opioid-mediated pain relief.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure, the brand team is likely in defensive/optimization mode with minimal growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SYNALGOS-DC offers limited high-visibility career growth opportunities due to its LOE-approaching lifecycle and minimal linked job openings. This role is ideal for professionals seeking stable, compliance-focused work in legacy product management rather than innovation-driven advancement.
Regulatory Affairs SpecialistPharmacovigilance Scientist
Worked on SYNALGOS-DC at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.